Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,185.71 -6.23 (-0.52%)
Official Closing Price Updated: 7:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
News headline image
The $180 Billion Gamble: Alphabet’s High-Stakes AI Transformation in 2026
Date: February 6, 2026 Introduction Alphabet Inc. (NASDAQ: GOOGL / GOOG) currently stands at the most consequential crossroads in its 28-year history. Once the undisputed king of the information age,... 
Via Finterra
Topics Artificial Intelligence Economy Initial Public Offering
These S&P500 stocks that are showing activity before the opening bell on Friday. ↗
Via Chartmill
News headline image
Walmart Just Became the Newest Member of the Trillion-Dollar Club, and These 2 Non-AI Stocks May Be Next -- but There's a Catch ↗
Two standout companies from the same sector (no, not technology) have a clear path to follow in Walmart's footsteps. 
Via The Motley Fool
Topics Artificial Intelligence Economy Government
News headline image
P/E Ratio Insights for Eli Lilly and Co ↗
 
Via Benzinga
Eli Lilly & Co (NYSE:LLY) Stands Out in Recent CANSLIM Growth Stock Screen ↗
Via Chartmill
News headline image
Eli Lilly Stock Has Over 20% Upside, Analysts Say: Retail Seeks Pharma 'Safe Haven' As FDA Targets GLP-1 Copycats ↗
The stock’s rise followed FDA Commissioner Marty Makary's warning against companies marketing illegal copycat drugs. 
Via Stocktwits
Topics Fraud Law Enforcement
News headline image
Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings. ↗
There's another fight brewing around GLP-1 drugs -- this time on the delivery side. 
Via The Motley Fool
News headline image
The Great Rebalancing: Why Investors are Fleeing Big Tech for the 'Safety' of Utilities and Healthcare
As of early February 2026, the long-standing dominance of high-growth technology and artificial intelligence (AI) stocks has hit a significant wall, triggering a massive "Great Rebalancing" across the... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most ↗
Via MarketBeat
News headline image
Trade War 2.0: 25% Tariffs on Chips, Cars, and Medicine Reshape the Global Supply Chain
The global economic landscape has been jolted in the opening weeks of 2026 as the United States government formalizes a series of aggressive 25% tariff proposals targeting the critical sectors of... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts
In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a... 
Via MarketMinute
Topics Earnings Economy
News headline image
ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company’s Directors and Officers for Breach of Fiduciary Duties – LLY
From Scott+Scott Attorneys at Law LLP
Via Business Wire
News headline image
Eli Lilly Just Delivered Fantastic News to Shareholders ↗
The stock price has climbed in the triple digits over three years. 
Via The Motley Fool
Topics Government
News headline image
Eli Lilly&#39;s 2026 Outlook Push Back Demand Fears: Analyst ↗
Cantor says Eli Lilly's 2026 outlook eases GLP-1 pricing worries, raises its price target, and expects strong sales growth driven by incretin drugs and orforglipron prescriptions. 
Via Benzinga
News headline image
Trump Administration To Launch TrumpRx Platform For Discounted Drugs Later On Thursday: Reports ↗
The medications that will be offered via the platform include Novo Nordisk’s popular weight-loss drug Wegovy, Eli Lilly and Company's Zepbound, Amgen’s cholesterol drug Repatha, and Merck’s diabetes... 
Via Stocktwits
Topics Economy Government World Trade
Thursday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
This Healthcare Company Believes Its GLP-1 Pill Could Be "Next in Line" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs. ↗
Structure Therapeutics has a promising GLP-1 drug that is about to enter phase 3 trials. 
Via The Motley Fool
News headline image
Why Eli Lilly (LLY) Shares Are Getting Obliterated Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 7.4% in the morning session after the company discontinued three clinical pipeline assets, including a gene therapy for dementia... 
Via StockStory
Topics Artificial Intelligence
News headline image
Healthcare Titans Propel Dow to Record Highs as GLP-1 Sales Spark Major Market Rotation
As the first week of February 2026 unfolds, a dramatic shift in investor sentiment has split the U.S. stock market. While technology and artificial intelligence stocks have faced a sharp pullback, the... 
Via MarketMinute
Topics Artificial Intelligence Earnings Intellectual Property
News headline image
Why Eli Lilly Stock Just Dropped ↗
Hims & Hers has a GLP-1 weight loss pill -- and it's the cheapest one out there. 
Via The Motley Fool
News headline image
HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling? ↗
The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month. 
Via Stocktwits
Topics Intellectual Property
News headline image
Eli Lilly Beats Q4 Estimates But Shares Slide: Analyst Expects &#39;Clear Runway Into Next Decade&#39; ↗
Eli Lilly beats Q4 estimates, backed by sales of Zepbound and Mounjaro. Analyst maintains outperform rating, raises PT to $1,300. 
Via Benzinga
News headline image
Alphabet Inc. (GOOGL): The AI Powerhouse Reaches a $400 Billion Milestone Amid Antitrust Crossroads
As of February 5, 2026, Alphabet Inc. (NASDAQ: GOOGL) stands at a historic crossroads. The company recently capped off a blockbuster fiscal year 2025, becoming the first digital advertising giant to... 
Via Finterra
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Hims Is Already Knocking Off Novo's Wegovy Pill — For Just $49 A Month ↗
Hims & Hers Health launched a knockoff version of Novo Nordisk's already popular weight-loss pill on Thursday. 
Via Investor's Business Daily
News headline image
The $1 Trillion Apothecary: A Deep-Dive Research Report on Eli Lilly (LLY)
As of February 5, 2026, Eli Lilly and Company (NYSE: LLY) stands as a paradigm-shifting titan in the global healthcare landscape. Having recently crossed the historic $1 trillion market capitalization... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles ↗
Via MarketBeat
News headline image
Expert Outlook: Eli Lilly and Co Through The Eyes Of 15 Analysts ↗
 
Via Benzinga
News headline image
Eli Lilly Shares Boosted BY GLP-1s ↗
On Wednesday, Eli Lilly reported earnings well above expectations, and its shares initially rose by 10%. 
Via Talk Markets
News headline image
Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party? ↗
Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can. 
Via The Motley Fool
News headline image
LLY Q4 Deep Dive: Obesity Medicines, Pipeline Progress, and Market Expansion Drive Outperformance
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 42.6% year on year to $19.29 billion. The company’s full-year... 
Via StockStory
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.